Now Recruiting for Light-for-PD Clinical Trial!
Watch Jimmy Choi, 5-time American Ninja Warrior and person with PD, talk about the benefits of the Light-for-PD clinical trial.
Know someone with Parkinson’s? If your loved one is managing PD, this could be the opportunity they’ve been hoping for. A new, at-home trial for PD is underway. No travel required.

Trusted by the Fox Trial Finder
Now Recruiting for LightforPd Clinical Trial!
Know someone with Parkinson’s? If your loved one is managing PD, this could be the opportunity they’ve been hoping for. A new, at-home trial for PD is underway. No travel required.
Watch Jimmy Choi, 5-time American Ninja Warrior and person with PD, talk about the benefits of the Light-for-PD clinical trial.

Trusted by the Fox Trial Finder
ADDRESSING MAJOR UNMET NEEDS
A Breakthrough Therapy for People Living with Parkinson’s Disease
Specialized phototherapy addresses both motor and non-motor symptoms
Over 11 million people worldwide live with Parkinson’s disease (PD), a number that is projected to double over the next 20 years. As with so many other neurodegenerative diseases, there have been no major breakthroughs in Parkinson’s disease in decades.
Our personalized at-home device promises to be one of the most significant therapeutic breakthroughs in Parkinson’s disease in decades. We have seen large improvements in our proof-of-concept studies – especially in addressing major unmet needs in Parkinson’s. We are initiating a pivotal trial of our key product, Celeste® specialized phototherapy, to confirm safety and sustained efficacy.
Despite the efficacy of dopaminergic drugs, people with PD continue to experience difficulties with unresolved motor symptoms and non-motor symptoms (e.g., sleep disorders, fatigue, and mood and cognitive problems). Impaired function significantly reduces quality of life for many, often preventing those living with PD from working, exercising, socializing, and doing the things they want to do.
We invite you to join us to improve the lives of individuals suffering from neurodegenerative diseases.
Seeing Specialized Phototherapy Clearly
Our non-invasive specialized phototherapy is well on its way to becoming a physician-prescribed standard of care.
When it comes to motor and non-motor symptoms of Parkinson’s, here’s what we’re seeing so far.

PROMISING RESULTS
and enjoyed improved quality of life.

NON-INVASIVE

LIFESTYLE FRIENDLY PROTOCOL
Trending Topics

PhotoPharmics Closes Oversubscribed $6 Million Series B Extension to Advance FDA Breakthrough Parkinson’s Device
Original Press Release Funding supports key milestones as the Pivotal, Phase 3 trial surpasses 200 enrolled participants SALT LAKE CITY – PhotoPharmics, a leader in specialized light therapy for neurodegenerative diseases, today announced the close of its...
PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial
Two-thirds enrolled in one of the largest remote Parkinson’s trials—redefining access and inclusion in therapeutic research Salt Lake City, Utah – PhotoPharmics announced today that its Pivotal, Phase 3 clinical trial, Light for PD™, has now reached 200...

10 Ways to Manage Your Parkinson’s Symptoms
Introduction Living with Parkinson's disease presents a unique set of challenges, both physically and emotionally. While medication plays a crucial role in managing the condition, a holistic approach that incorporates various lifestyle adjustments and self-care...

Available Diagnosis and Treatment for Parkinson’s
Introduction Parkinson’s is one of the most common neurodegenerative disorders, second only to Alzheimer’s. Globally, it affects around 1% of people over 60, making it the leading movement-related neurological condition. “Parkinson’s diagnosis and treatment options”...

PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board
PhotoPharmics, a pioneer in specialized phototherapy for neurodegenerative diseases, today announced the appointment of Robert A. Hauser, MD, MBA, as the new Chairman of its Clinical & Scientific Advisory Board (CSAB). Dr. Hauser assumes this leadership role...